{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.6","upperLimit":"96.2","value":"82.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive samotolisib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unexpected toxicity. Patients undergo an x-ray, CT, MRI, FDG-PET, and blood sample collection on study.","id":"OG000","title":"Treatment (Samotolisib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Percentage of Patients Experiencing Grade 3 or 4 Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}